BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...were difficult to isolate and expand. Newcos including GentiBio Inc., Kyverna Therapeutics Inc. and Sonoma...
BioCentury | Oct 1, 2020
Finance

Sonoma tops off series A as it builds broader Treg therapy pipeline

...Wendell Lim, which are now part of the toolbox at another Treg cell therapy company, Kyverna Therapeutics Inc....
BioCentury | Aug 11, 2020
Emerging Company Profile

GentiBio: combining trio of platforms to enhance Treg therapies

...a $40 million series A round, and Kyverna Therapeutics Inc....
BioCentury | Jul 21, 2020
Deals

With deal for Tizona, Gilead places latest bet on cancer immunosuppression

...at least one other deal this year involving immunosuppressive cells, a collaboration in January with Kyverna Therapeutics Inc....
BioCentury | Feb 21, 2020
Product Development

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

...the year. Sonoma Biotherapeutics debuted this month with a $40 million series A round, and Kyverna Therapeutics Inc....
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

...the team behind Cell Design Labs and its acquirers at Gilead Sciences Inc. (NASDAQ:GILD) launched Kyverna Therapeutics Inc....
BioCentury | Jan 14, 2020
Emerging Company Profile

Kyverna applies Tregs, CAR Ts to autoimmune diseases with $25M series A, Gilead deal

...diseases, lending more support to the notion that T cell therapies have benefits beyond cancer. Kyverna Therapeutics Inc....
Items per page:
1 - 7 of 7
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...were difficult to isolate and expand. Newcos including GentiBio Inc., Kyverna Therapeutics Inc. and Sonoma...
BioCentury | Oct 1, 2020
Finance

Sonoma tops off series A as it builds broader Treg therapy pipeline

...Wendell Lim, which are now part of the toolbox at another Treg cell therapy company, Kyverna Therapeutics Inc....
BioCentury | Aug 11, 2020
Emerging Company Profile

GentiBio: combining trio of platforms to enhance Treg therapies

...a $40 million series A round, and Kyverna Therapeutics Inc....
BioCentury | Jul 21, 2020
Deals

With deal for Tizona, Gilead places latest bet on cancer immunosuppression

...at least one other deal this year involving immunosuppressive cells, a collaboration in January with Kyverna Therapeutics Inc....
BioCentury | Feb 21, 2020
Product Development

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

...the year. Sonoma Biotherapeutics debuted this month with a $40 million series A round, and Kyverna Therapeutics Inc....
BioCentury | Feb 7, 2020
Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

...the team behind Cell Design Labs and its acquirers at Gilead Sciences Inc. (NASDAQ:GILD) launched Kyverna Therapeutics Inc....
BioCentury | Jan 14, 2020
Emerging Company Profile

Kyverna applies Tregs, CAR Ts to autoimmune diseases with $25M series A, Gilead deal

...diseases, lending more support to the notion that T cell therapies have benefits beyond cancer. Kyverna Therapeutics Inc....
Items per page:
1 - 7 of 7